Cell kinetics aspects of human malignant neuroepithelial tumors: A follow-up study

P. Gaetani, M. Danova, G. Butti, V. Silvani, S. Brugnatelli, R. Buttini, R. Knerich, A. Riccardi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The prognostic value of proliferative activity and DNA distribution (ploidy), determined by flow cytometry (FCM), was evaluated in 38 cases of human malignant neuroepithelial tumors. No statistically significant correlation was found between flow cytometric data and clinical outcome. In particular, there was no significant difference between mean survival in cases with percentage of cells in S-phase lower and higher than 5%, respectively. In 21 cases with unimodal DNA distribution, the mean survival was 11.7 months; in 17 cases with bimodal DNA distribution, the mean survival was 12.5 months. The difference was not statistically significant. In our experience, proliferative activity and ploidy do not correlate well with the clinical course and survival of patients with malignant neuroepithelial tumors. However, application of FCM may provide, aside from histopathologic examination, additional biologic information that may be valuable in understanding the variation observed in the course of individual patients.

Original languageEnglish
Pages (from-to)145-150
Number of pages6
JournalTumori
Volume74
Issue number2
Publication statusPublished - 1988

Fingerprint

Neuroepithelial Neoplasms
Survival
Ploidies
DNA
Flow Cytometry
S Phase

ASJC Scopus subject areas

  • Cancer Research

Cite this

Cell kinetics aspects of human malignant neuroepithelial tumors : A follow-up study. / Gaetani, P.; Danova, M.; Butti, G.; Silvani, V.; Brugnatelli, S.; Buttini, R.; Knerich, R.; Riccardi, A.

In: Tumori, Vol. 74, No. 2, 1988, p. 145-150.

Research output: Contribution to journalArticle

Gaetani, P. ; Danova, M. ; Butti, G. ; Silvani, V. ; Brugnatelli, S. ; Buttini, R. ; Knerich, R. ; Riccardi, A. / Cell kinetics aspects of human malignant neuroepithelial tumors : A follow-up study. In: Tumori. 1988 ; Vol. 74, No. 2. pp. 145-150.
@article{16f058bd8b3340eb95bb40d199508423,
title = "Cell kinetics aspects of human malignant neuroepithelial tumors: A follow-up study",
abstract = "The prognostic value of proliferative activity and DNA distribution (ploidy), determined by flow cytometry (FCM), was evaluated in 38 cases of human malignant neuroepithelial tumors. No statistically significant correlation was found between flow cytometric data and clinical outcome. In particular, there was no significant difference between mean survival in cases with percentage of cells in S-phase lower and higher than 5{\%}, respectively. In 21 cases with unimodal DNA distribution, the mean survival was 11.7 months; in 17 cases with bimodal DNA distribution, the mean survival was 12.5 months. The difference was not statistically significant. In our experience, proliferative activity and ploidy do not correlate well with the clinical course and survival of patients with malignant neuroepithelial tumors. However, application of FCM may provide, aside from histopathologic examination, additional biologic information that may be valuable in understanding the variation observed in the course of individual patients.",
author = "P. Gaetani and M. Danova and G. Butti and V. Silvani and S. Brugnatelli and R. Buttini and R. Knerich and A. Riccardi",
year = "1988",
language = "English",
volume = "74",
pages = "145--150",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Cell kinetics aspects of human malignant neuroepithelial tumors

T2 - A follow-up study

AU - Gaetani, P.

AU - Danova, M.

AU - Butti, G.

AU - Silvani, V.

AU - Brugnatelli, S.

AU - Buttini, R.

AU - Knerich, R.

AU - Riccardi, A.

PY - 1988

Y1 - 1988

N2 - The prognostic value of proliferative activity and DNA distribution (ploidy), determined by flow cytometry (FCM), was evaluated in 38 cases of human malignant neuroepithelial tumors. No statistically significant correlation was found between flow cytometric data and clinical outcome. In particular, there was no significant difference between mean survival in cases with percentage of cells in S-phase lower and higher than 5%, respectively. In 21 cases with unimodal DNA distribution, the mean survival was 11.7 months; in 17 cases with bimodal DNA distribution, the mean survival was 12.5 months. The difference was not statistically significant. In our experience, proliferative activity and ploidy do not correlate well with the clinical course and survival of patients with malignant neuroepithelial tumors. However, application of FCM may provide, aside from histopathologic examination, additional biologic information that may be valuable in understanding the variation observed in the course of individual patients.

AB - The prognostic value of proliferative activity and DNA distribution (ploidy), determined by flow cytometry (FCM), was evaluated in 38 cases of human malignant neuroepithelial tumors. No statistically significant correlation was found between flow cytometric data and clinical outcome. In particular, there was no significant difference between mean survival in cases with percentage of cells in S-phase lower and higher than 5%, respectively. In 21 cases with unimodal DNA distribution, the mean survival was 11.7 months; in 17 cases with bimodal DNA distribution, the mean survival was 12.5 months. The difference was not statistically significant. In our experience, proliferative activity and ploidy do not correlate well with the clinical course and survival of patients with malignant neuroepithelial tumors. However, application of FCM may provide, aside from histopathologic examination, additional biologic information that may be valuable in understanding the variation observed in the course of individual patients.

UR - http://www.scopus.com/inward/record.url?scp=0023923945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023923945&partnerID=8YFLogxK

M3 - Article

C2 - 3368968

AN - SCOPUS:0023923945

VL - 74

SP - 145

EP - 150

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 2

ER -